Esophagus cancer
Conditions
Interventions
Case series:None
Sponsors
Zhangzhou Affiliated Hospital of Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Sign written informed consent before implementing any trial-related procedures; 2. The patient's age is >=18 years old; 3. Patients diagnosed with esophageal cancer through histopathological examination of primary tumor biopsy; 4. Patients who are judged to be operable by imaging and esophagoscopy and need neoadjuvant therapy (cT2-3, N1-2M0), stage II-III; 5. According to the Response Evaluation Criteria for Solid Tumors (RECIST version 1.1), there is at least one lesion that can be measured by imaging; 6. The patient has not received any anti-tumor therapy before, including but not limited to surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, etc.; 7. ECOG score 0-1 points.
Exclusion criteria
Exclusion criteria: 1. Receive a live attenuated vaccine within 4 weeks before enrollment or plan to receive a live attenuated vaccine during the study; 2. Active, known or suspected autoimmune disease; 3. Known history of primary immunodeficiency; 4. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation; 5. Pregnant or breastfeeding female patients. 6. Untreated acute or chronic active hepatitis B or C infection. For patients receiving antiviral therapy, under the condition of monitoring the number of virus copies, the doctor will judge whether they are eligible for inclusion according to the individual situation of the patient; 7. Uncontrolled concurrent diseases, including but not limited to: (1) HIV-infected persons (HIV antibody positive); (2) Serious infection in active stage or poorly controlled clinically; (3) The presence of severe or uncontrolled systemic disease (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, hepatic or renal disease, uncontrolled hypertension [i.e. Refers to evidence of greater than or equal to CTCAE grade 2 hypertension after drug treatment]). 8. Those with active bleeding or new thrombotic disease who are taking therapeutic anticoagulant drugs or have bleeding tendency.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete pathological remission; | — |
Secondary
| Measure | Time frame |
|---|---|
| Major pathological remission;Safety;Disease free survival time; | — |
Countries
China
Contacts
Public ContactZhang Yi
Zhangzhou Affiliated Hospital of Fujian Medical University
Outcome results
None listed